News | Stroke | March 04, 2016

Imaging, not Time, May Determine Eligibility for Stroke Clot Removal

Researchers use CT perfusion to identify ischemic stroke patients who could benefit from endovascular therapy up to 18 hours after symptom onset

endovascular therapy, stroke clot removal, CT perfusion, brain imaging, International Stroke Conference study

March 4, 2016 — Brain imaging may accurately identify patients likely to benefit from stroke clot removal instead of relying on the time since symptoms began as an indicator of treatment eligibility. The hypothesis was derived from research presented at the American Stroke Association's International Stroke Conference 2016.

An ischemic stroke is caused by lack of blood reaching part of the brain. Endovascular treatment — which mechanically removes the blood clot blocking the path to the brain — benefits patients when performed within six hours of symptom onset. Drug treatment to bust the clot is beneficial up to 4.5 hours.

Here, researchers show that brain imaging can select patients who could benefit from clot removal up to 18 hours after stroke symptoms begin.

Researchers evaluated data on 102 patients who had endovascular therapy up to 18 hours after the start of their stroke and had a computed tomography perfusion (CTP) imaging scan before treatment that showed where a large area of brain tissue may be safely salvaged.

Good recovery — defined as little to no disability — was achieved in 71.4 percent of the patients treated within six hours and 61.7 percent of patients treated beyond six hours of stroke onset. There was no significant association between time to treatment and good outcomes when CT perfusion imaging shows a salvageable brain tissue.

"Using this image-based selection, we would be able to look at any patient who comes through the door to identify the ones likely to benefit from these therapies, regardless of what the clock shows," said Jenny Tsai, M.D., C.M., study author and neuroimaging and vascular neurology fellow at the Stanford Stroke Center. The facility is part of the University of Stanford's School of Medicine in Stanford, Calif.

"This is important because we want to offer the best treatments to every patient who suffers stroke and who may benefit from them. One of the best ways to do this is to have an objective imaging tool to evaluate every single patient," she said.

Researchers analyzed patient data from the clinical study CT Perfusion to predict Response to recanalization in Ischemic Stroke Project (CRISP). The two-year study focused on adults 18 and older and finished in 2014. It was funded by the NIH and conducted at six U.S. medical sites with the goal of developing a practical tool to identify acute stroke patients likely to benefit from endovascular therapy.

"We now have a very effective treatment for the large and disabling acute strokes," Tsai said. "And we know that there are patients likely to benefit from interventional treatments who are not being captured using basic imaging and time criteria alone. We need to do better."

Co-authors are Michael Mlynash, M.D., M.S.; Soren Christensen, Ph.D.; Stephanie Kemp; Nishant Mishra, M.D., Ph.D.; Christian Federau, M.D.; Dipl. Phys. ETH; Sun Kim, M.D.; Michael Frankel, M.D.; Seena Dehkharghani, M.D.; Thomas Devlin, M.D.; Dileep Yavagal, M.D.; Naveed Akhtar, M.D.; Tudor Jovin, M.D.; Raul Nogueira, M.D.; Roland Bammer, Ph.D.; Matus Straka, Ph.D.; Gregory Zaharchuk, M.D., Ph.D; Gregory Albers, M.D.; Michael Marks, M.D.; and Maarten Lansberg, M.D., Ph.D. Author disclosures are on the abstract.

The study was funded by the National Institutes of Health.

For more information: www.strokeconference.org

Related Content

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp